跨越曲妥珠单抗时代乳腺癌靶向治疗策略

Targeted therapy strategy for the treatment of breast cancer in the spanning trastuzumab era

乳腺癌是一个复杂的异质性疾病。随着分子生物学技术的进步,乳腺癌靶向治疗进展很快。从1997年美国食品与药物管理局(FDA)批准抗HER-2的分子靶向治疗药物——曲妥珠单抗治疗晚期乳腺癌,开创了乳癌分子靶向治疗的时代。以后有多靶点药物拉帕替尼、血管表皮生长因子抑制剂贝伐单抗相继用于临床治疗。还有很多批准用于其他恶性肿瘤的靶向药物如吉非替尼、索拉非尼等也有一些II期研究显示了在乳腺癌治疗中的活性。另外,T-DM1等新药也在进行II/III期临床研究。

Breast cancer is a complex and heterogeneous disease. Targeted therapies for breast cancer are evolving rapidly. Trastuzumab therapy for HER-2-positive metastatic breast cancer was approved by FDA in 1997. Since that day, other targeted therapies, such as lapatinib, a dual human epidermal growth factor receptor HER1 and HER-2 inhibitor, bevacizumab, a monoclonal antibody targeting angiogenesis, have been used in clinical practice. Other targeted drugs which have been approved in other cancer, such as gefitinib, sorafenib, have shown good activity in breast cancer. Additionally many new drugs like T-DM1 are being assessed in breast cancer.